Bio-Rad Laboratories, founded in 1952 and headquartered in the United States, operates within the manufacturing sector, specifically focusing on pharmaceuticals and medical devices. The company employs between 5,001 and 10,000 personnel and reported revenues of approximately $2.58 billion. Bio-Rad's published documents reflect a strong emphasis on oncology and cancer diagnostics, particularly through the analysis of circulating tumor cells (CTCs) and liquid biopsy techniques. Their research highlights the importance of non-invasive methods for cancer detection, diagnosis, and monitoring, as well as the potential for CTC analysis to inform treatment decisions. Additionally, Bio-Rad produces case studies that illustrate the application of their technologies in clinical settings, showcasing their commitment to advancing cancer research. The company also provides guides on quality control, emphasizing the significance of independent quality checks in laboratory processes. Overall, Bio-Rad's documentation underscores its expertise in medical diagnostics and its contributions to improving patient outcomes in oncology.